Tiziana Life Sciences Ltd (TLSA) Stock Price, Quote & News

Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: www.tizianalifesciences.com

Address:

14/15 Conduit Street, London, United Kingdom

Ashte Nov. 14 at 11:16 PM

$TLSA $MAGS needed the retest before the next leg up🤞🏻….if it breaks down the support line, then 367

1 · Reply

GoCubsGo1124 Nov. 14 at 8:59 PM

$TLSA interesting day. 🤔 have a good weekend all

0 · Reply

rp6577 Nov. 14 at 8:55 PM

$TLSA I think together Gabriele, Dauntless, Laura and Jorey now hold just over 50% of the company

1 · Reply

Bajan45 Nov. 14 at 6:28 PM

$TLSA Chernett Jorey buying another couple of million shares 🥰💵💵

2 · Reply

rp6577 Nov. 14 at 8:45 AM

$TLSA the share price could be in a very different place in a few weeks time

1 · Reply

Varus_q Nov. 14 at 7:57 AM

$TLSA Found this by accident and started digging deeper — and a lot of positive signals are lining up: - Management says no new capital raise planned → shows confidence in the current cash runway. - Insider buying from senior leadership → they clearly believe in upcoming data. - New CEO with strong biotech M&A background (Novartis, Biogen, Eli Lilly, Astellas). - Foralumab (SPMS) Phase 2 trial expanding to new sites and progressing well. To me this suggests they’re expecting positive topline data for foralumab. If results are good, raising funds later becomes easier with less dilution — or they may already be in early M&A discussions. Either way, setup looks strong. Not financial advice — DYOR.

1 · Reply

rp6577 Nov. 13 at 7:53 PM

$TLSA only a few weeks away from the big Phase 2 data

0 · Reply

GoCubsGo1124 Nov. 13 at 2:15 PM

$TLSA 🤔

1 · Reply

HopehelpsU Nov. 12 at 3:21 PM

$TLSA Wake up little gem 💎 ✨️..... I've posted enough proof here that the FDA requested more info for ODD approval.... Let's get it fooking done already!

0 · Reply

GoCubsGo1124 Nov. 11 at 10:00 PM

$TLSA didn’t the CEO and a board member by tens of thousands of shares at 1.60$ last month? Surely it won’t drop below that and they won’t take a loss. News comes out next month

0 · Reply

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Oct 31, 2025, 9:43 AM EDT - 14 days ago

Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot

Oct 29, 2025, 7:00 AM EDT - 16 days ago

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Sep 30, 2025, 8:30 AM EDT - 6 weeks ago

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

Sep 24, 2025, 8:30 AM EDT - 7 weeks ago

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

Sep 15, 2025, 8:00 AM EDT - 2 months ago

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Sep 9, 2025, 10:04 AM EDT - 2 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Sep 5, 2025, 8:30 AM EDT - 2 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Aug 14, 2025, 8:30 AM EDT - 3 months ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Aug 11, 2025, 9:00 AM EDT - 3 months ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Jul 21, 2025, 7:00 AM EDT - 4 months ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jun 13, 2025, 11:08 PM EDT - 5 months ago

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

Jun 13, 2025, 10:30 AM EDT - 5 months ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 8:30 AM EDT - 5 months ago

Tiziana Life Sciences to Present at the Bio International Convention

May 23, 2025, 7:00 AM EDT - 6 months ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 6 months ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 9, 2025, 7:00 AM EDT - 6 months ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 6, 2025, 7:00 AM EDT - 6 months ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Apr 23, 2025, 7:00 AM EDT - 7 months ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 2, 2025, 8:00 AM EDT - 8 months ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Mar 25, 2025, 8:00 AM EDT - 8 months ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 17, 2025, 8:00 AM EDT - 8 months ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 14, 2025, 8:30 AM EDT - 8 months ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 4, 2025, 8:00 AM EST - 9 months ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Feb 27, 2025, 8:00 AM EST - 9 months ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 25, 2025, 8:00 AM EST - 9 months ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 21, 2025, 8:00 AM EST - 9 months ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 18, 2025, 8:00 AM EST - 9 months ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Feb 11, 2025, 9:15 AM EST - 9 months ago

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Jan 23, 2025, 3:00 PM EST - 10 months ago

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Jan 23, 2025, 8:54 AM EST - 10 months ago

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Jan 22, 2025, 4:05 PM EST - 10 months ago

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Jan 8, 2025, 7:00 AM EST - 11 months ago

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

Nov 1, 2024, 1:00 PM EDT - 1 year ago

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Oct 30, 2024, 10:29 PM EDT - 1 year ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Appoints New Chief Executive Officer

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Granted FDA Fast Track Designation

Jun 28, 2024, 11:01 AM EDT - 1 year ago

Tiziana Receives $3.4 Million in Non-Dilutive Funding

Jun 26, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab

May 30, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

May 13, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab

Apr 25, 2024, 10:00 AM EDT - 1 year ago

Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program

Apr 22, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program

Apr 19, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Mar 5, 2024, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease

Jan 8, 2024, 7:00 AM EST - 2 years ago

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Jan 5, 2024, 9:30 AM EST - 2 years ago

Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

Ashte Nov. 14 at 11:16 PM

$TLSA $MAGS needed the retest before the next leg up🤞🏻….if it breaks down the support line, then 367

1 · Reply

GoCubsGo1124 Nov. 14 at 8:59 PM

$TLSA interesting day. 🤔 have a good weekend all

0 · Reply

rp6577 Nov. 14 at 8:55 PM

$TLSA I think together Gabriele, Dauntless, Laura and Jorey now hold just over 50% of the company

1 · Reply

Bajan45 Nov. 14 at 6:28 PM

$TLSA Chernett Jorey buying another couple of million shares 🥰💵💵

2 · Reply

rp6577 Nov. 14 at 8:45 AM

$TLSA the share price could be in a very different place in a few weeks time

1 · Reply

Varus_q Nov. 14 at 7:57 AM

1 · Reply

rp6577 Nov. 13 at 7:53 PM

$TLSA only a few weeks away from the big Phase 2 data

0 · Reply

GoCubsGo1124 Nov. 13 at 2:15 PM

$TLSA 🤔

1 · Reply

HopehelpsU Nov. 12 at 3:21 PM

$TLSA Wake up little gem 💎 ✨️..... I've posted enough proof here that the FDA requested more info for ODD approval.... Let's get it fooking done already!

0 · Reply

GoCubsGo1124 Nov. 11 at 10:00 PM

$TLSA didn’t the CEO and a board member by tens of thousands of shares at 1.60$ last month? Surely it won’t drop below that and they won’t take a loss. News comes out next month

0 · Reply

Michael_Krombopulos Nov. 11 at 2:32 PM

$DFLI ER coming up. Currently undervaluded relative to peers, high growth expections with strong revenue growth forcast (~38% annum over next 3 years). New patents, new global distribution partners, new OEM partnerships. RVs, Marine, Off-Grid, Carts, etc. IP and partnerships matter in this sector and they now have all the pieces IMO. After the debt restructuring (bullishly) and reaching compliance goals 2 weeks ago, and IMO this is really poised to breakout again even if you are just looking for a low float setup. Do some DD quick $NVDA $TLSA

0 · Reply

GoCubsGo1124 Nov. 10 at 9:28 PM

$TLSA had to sell some and move some of my huge loss to BBAI and its 2x leveraged etf in hopes to make it back after their earnings beat. Sucks to have to do that as I’ve put so much hope and money into this company. I’ll be back on the further dip.

0 · Reply

GoCubsGo1124 Nov. 10 at 9:20 PM

$TLSA DO SOMETHING! Ffs

0 · Reply

Greenthought Nov. 10 at 6:47 PM

$ELPW $TGE $TLSA $XMTR

0 · Reply

Greenthought Nov. 10 at 11:03 AM

$TGE $XMTR $TLSA $ELPW

1 · Reply

GoCubsGo1124 Nov. 10 at 1:53 AM

$TLSA let’s have a good week chat

0 · Reply

HopehelpsU Nov. 10 at 12:10 AM

$TLSA FUTURES JUMPING!

0 · Reply

GoCubsGo1124 Nov. 9 at 4:44 PM

$AMPX in someways this chart reminds me where $TLSA could go if it gained some tailwinds. 🤔 similar bounces around the .86 mark up to the 3$ mark.

0 · Reply

GoCubsGo1124 Nov. 7 at 10:27 PM

$TLSA wtf? Just dropped to 1.69 with a 3k sell on Webull after hours. Why am I holding watching my money disappear? 🤦🏼‍♂️

1 · Reply

GoCubsGo1124 Nov. 7 at 4:02 PM

$TLSA @Smedley1 you know they are waiting for us to sell our shares and then they will fill send it. It’s frustrating but I’ve got time.

0 · Reply

GoCubsGo1124 Nov. 7 at 3:34 PM

$TLSA every time it tries…shorted back down. Dumb!

0 · Reply

HopehelpsU Nov. 6 at 8:40 PM

$TLSA Nobody mentions it, but this little turd company could be a buyout target. I could see $10 easy in a buyout..

2 · Reply

Market Cap	192.80M
Revenue (ttm)	0.00
Net Income (ttm)	-11.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	157,100
Avg Vol	348,194
Day's Range	N/A - N/A
Shares Out	116.85M
Stochastic %K	46%
Beta	-0.34
Analysts	Strong Buy
Price Target	$3.00